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Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia, a commercially expensive
respiratory disease of swine. Salmonella typhimurium SL3261 was used as a live carrier of plasmid pKF1, which
encodes a 15-kDa recombinant M. hyopneumoniae protein. This expressed recombinant protein consists of the
carboxy-terminal 11 kDa of a 42-kDa M. hyopneumoniae NrdF ribonucleotide reductase R2 subunit protein.
Rabbit anti-15-kDa serum was able to inhibit the growth of viable M. hyopneumoniae J in vitro. When used as
a live oral vaccine, S. typhimurium SL3261(pKF1) induced a significant secretory immunoglobulin A immune
response in the lungs of mice orally immunized against the M. hyopneumoniae antigen. Utilization of live oral
vaccines expressing potentially protective M. hyopneumoniae proteins, such as the NrdF antigen, which can
stimulate a lung mucosal response against surface-accessible proteins may provide a cost-effective alternative
to the present control strategies used for porcine enzootic pneumonia.
Mycoplasma hyopneumoniae is the etiological agent of por-
cine enzootic pneumonia (PEP), a chronic respiratory disease
of pigs (29) which inflicts severe economic losses on pig pro-
ducers worldwide (21, 24). This pathogen colonizes the respi-
ratory epithelia of swine and compromises their integrity
through the induction of an inflammatory response (3, 25).
Without complications from secondary bacterial pathogens,
clearance of M. hyopneumoniae and resolution of lung lesions
can occur after 4 to 5 weeks (1, 19). However, M. hyopneu-
moniae infection predisposes pigs to secondary invaders, such
as Pasteurella multocida (9) and Actinobacillus pleuropneumo-
niae (38), which exacerbate economic losses and may increase
mortality. M. hyopneumoniae infection rates within herds can
vary between 30 and 80% (29). Current control strategies rely
upon animal management procedures (10) and the use of an-
tibiotics. However, as antibiotic usage in food producing ani-
mals is increasingly losing favor (37) and as swine are the only
hosts for this pathogen, it is feasible and desirable that control
of the disease be achieved with strict husbandry practices and
an effective vaccination regime. Previous research by our group
has shown that the 15-kDa M. hyopneumoniae antigen is
strongly recognized by swine hyperimmune sera. This recom-
binant antigen was identified as containing part of a 42-kDa M.
hyopneumoniae NrdF protein which is the R2 subunit of the
essential prokaryotic class I ribonucleotide reductase (12). The
carboxy-terminal 11 kDa of the M. hyopneumoniae NrdF anti-
gen was expressed as a 128-kDa b-galactosidase fusion protein
in Escherichia coli. Preliminary pig trials with purified 128-kDa
fusion protein delivered intramuscularly resulted in a signifi-
cant reduction in PEP in vaccinated animals compared with
unvaccinated controls following experimental challenge (12),
indicating that the recombinant NrdF protein is a potential
candidate antigen for use in M. hyopneumoniae vaccines.
To date there have been no reports describing the use of
attenuated Salmonella typhimurium aroA vectors for the deliv-
ery of mycoplasmal antigens. Previous studies using S. typhi-
murium aroA (15) have demonstrated that these strains are
invasive yet nonvirulent and capable of eliciting immune re-
sponses which protect against subsequent virulent challenge (6,
15, 20, 23). After ingestion, S. typhimurium attaches to, in-
vades, and proliferates within intestinal enterocytes (7), even-
tually reaching the basal epithelial cells from which it may
traverse the intestinal barrier and colonize the liver, spleen,
and mesenteric lymph nodes (13). Of particular importance to
live oral immunization strategies is the invasion of the M cells
which overlie the Peyer’s patches of the intestinal mucosa,
important components of the gut-associated lymphoid tissue
(GALT) (28). Antigen processing and presentation within the
GALT results in the migration of specific B and T cells to distal
mucosal regions (4) which are primed for a specific secretory
immune response. Attenuated S. typhimurium aroA mutants
are able to survive for up to 7 days in situ, which is a sufficient
period for colonization and limited growth within the invaded
intestinal cells (8). After this period the bacteria are no longer
viable and cannot avoid the host cell defenses; subsequently,
the bacteria are recognized and processed. Studies have also
demonstrated that these attenuated strains are able to deliver
plasmid-encoded mucosal pathogen antigens via the GALT
pathway, resulting in the priming of immune cells in the lung
against these heterologous antigens (6, 14, 35). This report
describes the expression of a 15-kDa fusion protein containing
11 kDa of M. hyopneumoniae NrdF antigen in S. typhimurium
SL3261(pKF1), and the potential of this live recombinant vac-
cine strain to elicit mucosal immunoglobulin A (IgA) in mice
was examined.
To determine the accessibility and essential nature of the
native NrdF protein in M. hyopneumoniae, growth inhibition
assays were carried out by a procedure described by Stanbridge
and Hayflick (30). Sterile discs impregnated with rabbit anti-
15-kDa NrdF serum (Fig. 1B) and swine hyperimmune anti-M.
hyopneumoniae serum (Fig. 1A) inhibited the growth of freshly
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cultured M. hyopneumoniae. A distinct clearing zone was ob-
served around the perimeter of the disc (Fig. 1A and B) and is
in marked contrast to the absence of such zones around the
rabbit prevaccination bleed-impregnated disc (Fig. 1C) and a
swine prevaccination prebleed disc (data not shown). Zones of
clearance around the 6-mm-diameter disc were found to be
approximately 3 mm wide when observed by light microscopy.
The zones of inhibition are a product of the inhibited growth of
M. hyopneumoniae. Clearing increases closer to the disc, pre-
sumably due to increased antibody concentrations. Zones of
clearance are reduced when stained with Coomassie brilliant
blue because the extreme regions of the zones contain limited
amounts of mycoplasmal growth which readily stain when this
sensitive visualization technique is used.
Plasmid pKF1 containing a 0.8-kb mycoplasmal DNA frag-
ment encoding the NrdF antigen (12) was used to transform
(27) S. typhimurium SL3261 (15), resulting in the expression of
a 15-kDa recombinant protein (Fig. 2) as determined by poly-
acrylamide gel electrophoresis (17) and Western immunoblot-
ting (5) using rabbit 15-kDa NrdF antiserum. This expressed
antigen was purified and consists of 11 kDa from the carboxy-
terminal region of the 42-kDa M. hyopneumoniae NrdF protein
(12), with the remainder being 4 kDa encoded by the polyclon-
ing site of pHSG398 (32). The recombinant protein is consti-
tutively expressed in S. typhimurium from the lactose promoter
because the pHSG398 vector does not contain a lactose re-
pressor gene. Mice immunization trials were performed to
assess the ability of the S. typhimurium SL3261(pKF1) vaccine
strain to elicit anti-M. hyopneumoniae secretory and serum
antibody responses. Immunization was performed essentially
as described by Guzma´n et al. (14). Six- to eight-week-old
female BALB/c mice were caged separately according to treat-
ment groups. For live oral vector control and vaccine groups,
cultures were grown to mid-logarithmic phase, pelleted by cen-
trifugation (2,000 3 g for 15 min), and subsequently resus-
pended in ice-cold phosphate-buffered saline (PBS; pH 7.2) to
an optical density corresponding to 2 3 109 viable bacteria per
100 ml. Immediately prior to immunization an equal volume of
3% sodium bicarbonate in PBS (pH 7.2) was added to give the
final working dilution of 109 viable bacteria per 100 ml. Mice in
all oral vaccine groups were deprived of water for 2 to 3 h
before delivery of the vaccine (100 ml of the bacterial suspen-
sion) through an esophageal cannula. For intraperitoneal (i.p.)
immunization, a total of 50 mg of 15-kDa NrdF protein was
diluted in 50 ml of PBS (pH 7.2) and emulsified in an equal
volume of Freund’s complete adjuvant to give the final 100-ml
injection volume for the primary immunization. In subsequent
booster immunizations Freund’s incomplete adjuvant was
used, while the volume and antigen dose remained identical to
those of the primary immunization. All mice received primary
immunizations at day 0 and boosters at days 30 and 40 and
were sacrificed at day 50. Mice were killed by cervical disloca-
tion prior to exsanguination by the severing of the brachial
artery. Sera were collected and stored at 220°C. Lung lavages
were collected by pertracheal cannulation by instilling 0.8 ml of
PBS containing 2 mM phenylmethylsulfonyl fluoride. Lung
lavages were centrifuged briefly (3,000 3 g) to remove partic-
ulate matter and were stored at 220°C. An enzyme-linked
immunosorbent assay (ELISA) was used to determine mouse
antibody responses for IgA, IgM, and IgG isotypes in sera and
lung lavage samples. The primary antigen was either 15-kDa
NrdF protein diluted to a final concentration of 1 mg/ml in
carbonate buffer (30 mM sodium carbonate, 20 mM sodium
hydrogen carbonate, pH 9.6) or S. typhimurium SL3261 whole-
cell lysate prepared by boiling 10 mg of cell pellet for 10 min in
0.5 M Tris-HCl (pH 6.8) containing 1% glycerol, 0.2% sodium
dodecyl sulfate, and 0.5% b-mercaptoethanol. Whole-cell ly-
sate was then pelleted (16,000 3 g for 3 min at room temper-
ature) to remove debris, and the protein concentration was
adjusted to 1 mg/ml in carbonate buffer prior to use. Aliquots
(100 ml) of the primary antigen were used to coat 96-well
microtiter plates (Nunc) by incubation for 1 h at 37°C. Plates
were subsequently washed five times with 0.05% Tween 20
(Sigma) in PBS (pH 7.4). The first antibody was mouse sera
diluted 1 in 200 or lung lavage samples diluted 1 in 20; in both
cases the diluent was PBS containing 10% fetal bovine serum
and 0.05% Tween 20. Aliquots (100 ml) of the first antibody
were added in triplicate and incubated for 1 h at 37°C. Fol-
lowing incubation, plates were washed as previously described
and 100-ml aliquots of horseradish peroxidase-conjugated rab-
bit anti-mouse Ig antibodies (Bio-Rad) diluted in PBS (pH 7.4)
FIG. 1. Growth inhibition assay using sterile paper discs (6 mm in diameter)
impregnated with different serum samples overlaid onto a lawn of freshly cul-
tured M. hyopneumoniae J. Inhibition of growth can be seen as a halo-like ring
(indicated by an arrow) around the darker area where the paper disc was located.
Inhibition can be seen around the discs impregnated with hyperimmune pig
serum (A) and rabbit 15-kDa NrdF antiserum (B). No zone of clearing was
detected around the rabbit prebleed serum (C).
FIG. 2. Expression and identification of M. hyopneumoniae NrdF recombi-
nant antigen in S. typhimurium SL3261. (A) Coomassie brilliant blue-stained
15% polyacrylamide gel electrophoresis gel. Lane 1, S. typhimurium SL3261; lane
2, purified recombinant 15-kDa NrdF antigen; lane 3, S. typhimurium SL3261
(pKF1); lane 4, S. typhimurium SL3261(pHSG398). (B) Western blot analysis of
the same samples described above using rabbit M. hyopneumoniae 15-kDa NrdF
serum. The sizes of molecular mass markers (in kilodaltons) and that of the
recombinant NrdF protein (arrowhead) are indicated.
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containing 10% fetal bovine serum and 0.05% Tween 20 were
added to each well. Rabbit anti-IgG (KPL) and anti-IgM
(KPL) second antibodies were diluted 1 in 2,000, whereas
anti-IgA (KPL) was diluted 1 in 400. Plates were incubated at
37°C for 1 h and were then washed as described above. ELISA
plates were developed with 100-ml aliquots of tetramethylben-
zidine dihydrochloride (Sigma); development was stopped af-
ter 3 min by the addition of 50 ml of 0.1 M phosphoric acid, and
the absorbance was read at 450 nm. The plates were blanked
against a PBS control, and the variation between plates was
standardized with positive control sera, allowing isotype com-
parisons between groups. Antibody responses were compared
by using a Tukey multiple comparison test for unequal sample
sizes as described by Zar (39).
Oral delivery of the live S. typhimurium SL3261(pKF1) vac-
cine strain to mice elicited anti-M. hyopneumoniae NrdF IgA
antibody responses in the lungs of vaccinated mice (Fig. 3C,
graph c) but did not elicit significant (P ,0.05) IgG (Fig. 3C,
graph c) or IgM (data not shown) isotype responses in the
serum or lungs. i.p. immunization with the purified 15-kDa
NrdF antigen elicited significant serum IgG (Fig. 3A, graph d),
IgM (data not shown), and lung IgG (Fig. 3C, graph d) re-
sponses against this antigen. The absence of IgM antibody in
lung lavage samples precludes the possibility of serum contam-
FIG. 3. Levels of recombinant 15-kDa NrdF-specific IgG and IgA antibodies in mouse serum and lung lavage samples after vaccination. (A) Serum antibody levels
specific for 15-kDa NrdF protein. (B) Serum antibody levels specific for S. typhimurium SL3261 whole-cell proteins. (C) Lung lavage antibody levels specific for 15-kDa
NrdF protein. (D) Lung lavage antibody levels specific for S. typhimurium SL3261 whole-cell proteins. The standard errors of the means are indicated by vertical lines.
Statistical significance (P , 0.05) determined by comparing treatments against the PBS oral control group is indicated by asterisks.
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ination of the mucosal washes (data not shown). Thus, the
isotypes detected in the mouse lung samples can be considered
an accurate indication of the Ig isotypes present. For mice
from groups orally immunized with S. typhimurium SL3261,
there was a significant (P , 0.05) anti-salmonella IgG response
in serum (Fig. 3B, graphs b and c) and a significant IgA re-
sponse in lung lavage samples (Fig. 3D, graphs b and c). These
results confirm that the salmonella vector is being recognized
and processed by the host immune system. However, the i.p.
delivery of the M. hyopneumoniae NrdF protein also induced
significant serum IgG (Fig. 3B, graph d) and lung IgG S.
typhimurium antibody responses (Fig. 3D, graph d), indicating
cross-reactivity between the recombinant NrdF protein and
epitopes found in S. typhimurium SL3261 as previously de-
scribed (12).
The accessibility of the NrdF antigen on the surfaces of
intact M. hyopneumoniae cells was examined by whole-cell
ELISA. The primary antigen was 100 ml of M. hyopneumoniae
whole-cell suspension (0.03 A650 units) in 0.20 mM Tris-HCl
(pH 7.2) containing 10% methanol coupled to microtiter plates
(Linbro) by centrifugation (2,000 3 g for 30 min). The super-
natant was subsequently removed, 200 ml of blocking solution
(2% skim milk in PBS) was added, and the plates were incu-
bated for 1 h at room temperature and then washed and pro-
cessed as described previously. There were significant secre-
tory IgA levels (P , 0.05) in the lung washes of the live orally
vaccinated mice; this IgA recognized the cell surface of M.
hyopneumoniae in a whole-cell ELISA (Fig. 4B, graph c). Sig-
nificant serum IgG in the i.p. immunized 15-kDa treatment
group (Fig. 4A, graph d) was also observed.
Bacterin vaccines are relatively expensive because myco-
plasma culture is time-consuming, medium components are
expensive, and relatively poor bacterial yields are achieved. In
addition, protection against subsequent infection and improve-
ment in growth rates of swine are variable (18, 22). Little is
known about the protective mechanism effective against my-
coplasmal infection, including the identities of antigens re-
sponsible for evoking a protective immune response. Several
studies have demonstrated that M. hyopneumoniae attaches to
cilial tufts which line the epithelium of the bronchioles and
trachea of the pig; M. hyopneumoniae has never been observed
intracellulary (16, 31). The secretion of antibodies to mucosal
surfaces is believed to be pivotal in the inhibition of adherence
and cytotoxicity and also in the blocking of essential metabolic
processes, and as such the generation of mucosal gA against
specific antigens is likely to afford protection (26, 36). We
have demonstrated that S. typhimurium SL3261(pKF1)
evoked a mucosal IgA response specifically against a 15-kDa
recombinant M. hyopneumoniae NrdF antigen. In addition we
demonstrated that these antibodies bound to the surface of M.
hyopneumoniae in a whole-cell ELISA.
Attenuated recombinant vaccines, with S. typhimurium aroA
as the delivery vector, may provide cheap and easily adminis-
trable vaccines. M. hyopneumoniae predisposes swine to poten-
tially devastating secondary infections. Targeting the ribonu-
cleotide reductase NrdF protein of M. hyopneumoniae may
lead to an efficacious vaccine as this enzyme appears to be
essential to the metabolic process. NrdF catalyzes the conver-
sion of ribonucleoside diphosphates to deoxyribonucleoside
diphosphates, an essential step in DNA replication (34). Inhi-
bition studies of the herpes simplex virus type 1 (33) and E. coli
(11) ribonucleotide reductase enzymes suggest that the region
of the NrdF protein that is targeted (with nonapeptides) caus-
ing inhibition is the same carboxy-terminal region that is ex-
pressed in the S. typhimurium SL3261(pKF1) oral vaccine. In
the physiology of M. hyopneumoniae, the absence of a cell wall
FIG. 4. Levels of recombinant 15-kDa NrdF-specific IgG and IgA antibodies in mouse serum (A) and lung lavage samples (B) detected by whole-cell M.
hyopneumoniae ELISA. The standard errors of the means are indicated by vertical lines. Statistical significance (P , 0.05) determined by comparing treatments against
the PBS oral control group is indicated by asterisks.
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and outer membrane makes this pathogen particularly vulner-
able to neutralizing antibodies (2, 36). Our whole-cell ELISA
demonstrates the surface accessibility of the in situ NrdF pro-
tein in M. hyopneumoniae to specific antibodies raised in orally
vaccinated mice (Fig. 4).
The recombinant 15-kDa antigen encoded by plasmid pKF1
has no carrier molecule that would direct the protein to the cell
surface or elsewhere. Interestingly, there is no requirement to
use strategies to surface express the NrdF antigen in order to
promote a lung mucosal IgA response after oral vaccination.
Due to a demonstrated 48.4% identical amino acid homology
with S. typhimurium NrdF, and an 86.6% homology if con-
served amino acids are considered, some degree of cross-reac-
tivity is expected between the NrdF M. hyopneumoniae antigen
and the NrdF protein of S. typhimurium (12). This does not
present a problem in the detection of NrdF-specific antibody
responses. Antibodies raised against the M. hyopneumoniae
NrdF antigen recognize cross-reactive epitopes in the S. typhi-
murium SL3261 ELISA, resulting in high absorbance values in
this ELISA due to the excess of S. typhimurium antigen coating
in the assay wells. The lack of antibody response in the S.
typhimurium SL3261 oral control groups against M. hyopneu-
moniae NrdF protein (Fig. 3A and C, graph b) indicates that the
bacterial cross-reactive antigen is not immunogenic. This could be
because either the S. typhimurium protein is not being expressed
in sufficiently large quantities or the bacterial antigen is not being
processed and presented to the host immune system.
The successful oral immunization against a heterologous M.
hyopneumoniae antigen in a bacterial vector has not been pre-
viously reported. This study is unique not only because it dem-
onstrates that there were no problems associated with the
adenosine-tyrosine bias and different codon usage between the
selected mycoplasma antigen and salmonella vector but also
because it demonstrates that an immune response specific for
this antigen can reduce the severity of PEP in swine (12).
Although the physiologies of the mucosal immune systems of
mice and pigs are different, the induction in mice of a secretory
response against an essential metabolic protein from a swine
respiratory pathogen leads to the exciting prospect of conduct-
ing trials of this oral recombinant vaccine in pigs.
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